Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Centre for Reviews and Dissemination, University of York:

  • Norman G, Soares M, Peura P, et al., Capecitabine for the treatment of advanced gastric cancer, February 2010

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope. Organisations listed in I were also invited to make written submissions. Organisations listed in II gave their expert views on capecitabine by providing a written statement to the Committee. Organisations listed in I, II and III have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • Roche Products (capecitabine)

II) Professional/specialist and patient/carer groups:

  • Cancer Research UK

  • Macmillan Cancer Support

  • Royal College of Nursing

  • Royal College of Physicians, Medical Oncology Joint Special Committee

III) Other consultees:

  • Department of Health

  • Welsh Assembly Government

IV) Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • National Institute for Health Research Health Technology Assessment Programme

  • NHS Centre for Reviews & Dissemination and Centre for Health Economics – York

  • NHS Quality Improvement Scotland

C. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on capecitabine by providing oral evidence to the Committee.

  • Dr Alicia Okines, Clinical Research Fellow, nominated by The Royal College of Physicians – clinical specialist

  • Dr Anne L Thomas, Senior Lecturer in Medical Oncology, nominated by The Royal College of Physicians – clinical specialist

  • Abrar Hussain-Qureshi, nominated by Macmillan Cancer Support – patient expert

D. Representatives from the following manufacturer/sponsor attended Committee Meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Roche Products

  • National Institute for Health and Care Excellence (NICE)